Target Name: CACNB4
NCBI ID: G785
Other Name(s): CACNB4 variant 2 | EIG9 | CACB4_HUMAN | calcium channel voltage-dependent subunit beta 4 | CACNLB4 | Calcium voltage-gated channel auxiliary subunit beta 4, transcript variant 2 | calcium voltage-gated channel auxiliary subunit beta 4 | Calcium channel voltage-dependent subunit beta 4 | EJM6 | EA5 | CAB4 | Voltage-dependent L-type calcium channel subunit beta-4 | EJM | EJM4 | dihydropyridine-sensitive L-type, calcium channel beta-4 subunit | Voltage dependent calcium channel beta 4 subunit | Voltage-dependent L-type calcium channel subunit beta-4 (isoform b) | Dihydropyridine-sensitive L-type, calcium channel beta-4 subunit

CACNB4: A Potential Drug Target and Biomarker

CACNB4 (CACNB4 variant 2) is a protein that is expressed in the nervous system and has been identified as a potential drug target or biomarker. The protein is composed of 216 amino acids and has a calculated molecular weight of 23.9 kDa. It is localized to the endoplasmic reticulum and is expressed in various tissues, including the brain, heart, and skeletal muscles.

CACNB4 is involved in the regulation of neural transmission, which is critical for the function of the nervous system. It is a component of the neurotransmitter transporter, which is responsible for transporting neurotransmitters from the axon to the dendrites of neurons. It is also involved in the regulation of ion channels, which are responsible for the flow of electrical signals through the nervous system.

One of the unique features of CACNB4 is its ability to interact with several different neurotransmitters, including dopamine, serotonin, and GABA. This makes it a promising target for drugs that are designed to modulate these neurotransmitters. CACNB4 is also known to play a role in the regulation of pain perception, which is an important biomarker for several diseases, including chronic pain and neurodegenerative disorders.

In addition to its role in neural transmission and pain perception, CACNB4 is also involved in the regulation of several other cellular processes. For example, it is involved in the regulation of cell survival, cell proliferation, and cell migration. the regulation of inflammation, which is important for the development and progression of several diseases, including neuroinflammatory disorders.

CACNB4 is also a good candidate for a biomarker in neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles, which are thought to be a hallmark of these diseases. CACNB4 has been shown to be expressed in the brains of individuals with Alzheimer's disease and may be a potential biomarker for this condition.

In conclusion, CACNB4 is a protein that is expressed in the nervous system and has been identified as a potential drug target or biomarker. Its role in neural transmission, pain perception, and other cellular processes makes it a promising target for drugs that are designed to modulate these processes. In addition to its potential drug-targeting properties, CACNB4 is also a good candidate for a biomarker in neurodegenerative diseases. Further research is needed to fully understand the role of CACNB4 in these conditions and to develop effective treatments.

Protein Name: Calcium Voltage-gated Channel Auxiliary Subunit Beta 4

Functions: The beta subunit of voltage-dependent calcium channels contributes to the function of the calcium channel by increasing peak calcium current, shifting the voltage dependencies of activation and inactivation, modulating G protein inhibition and controlling the alpha-1 subunit membrane targeting

More Common Targets

CACNG1 | CACNG2 | CACNG2-DT | CACNG3 | CACNG4 | CACNG5 | CACNG6 | CACNG7 | CACNG8 | CACTIN | CACTIN-AS1 | CACUL1 | CACYBP | CAD | CADM1 | CADM2 | CADM3 | CADM3-AS1 | CADM4 | CADPS | CADPS2 | CAGE1 | CAHM | CALB1 | CALB2 | CALCA | CALCB | Calcium channel | Calcium release-activated channel (CRAC) | Calcium-activated chloride channel regulators | Calcium-Activated K(Ca) Potassium Channel | CALCOCO1 | CALCOCO2 | CALCR | CALCRL | CALCRL-AS1 | CALD1 | CALHM1 | CALHM2 | CALHM3 | CALHM4 | CALHM5 | CALHM6 | CALM1 | CALM2 | CALM2P1 | CALM2P2 | CALM3 | CALML3 | CALML3-AS1 | CALML4 | CALML5 | CALML6 | Calmodulin | CALN1 | Calpain | Calpain-13 | Calprotectin | CALR | CALR3 | CALU | CALY | CAMK1 | CAMK1D | CAMK1G | CAMK2A | CAMK2B | CAMK2D | CAMK2G | CAMK2N1 | CAMK2N2 | CAMK4 | CAMKK1 | CAMKK2 | CAMKMT | CAMKV | CAMLG | CAMP | cAMP Phosphodiesterase | cAMP Responsive Element Binding Protein (CREB) | cAMP-Dependent protein kinase (PKA) | CAMSAP1 | CAMSAP2 | CAMSAP3 | CAMTA1 | CAMTA2 | CAND1 | CAND1.11 | CAND2 | Cannabinoid receptor | CANT1 | CANX | Cap-binding complex | CAP1 | CAP2 | CAPG | CAPN1 | CAPN10 | CAPN10-DT | CAPN11